Cancer remains one of the world’s most significant healthcare challenges, driving efforts to develop more effective and personalized treatments. In the clinic, imaging supports cancer detection, diagnosis, staging, treatment planning, and monitoring of therapeutic response.
In preclinical oncology research, non-invasive in vivo imaging enables researchers to investigate tumor biology, disease progression, metastasis, treatment efficacy, and drug safety in real time within the complex environment of a living model.
By combining complementary anatomical, functional, and molecular modalities, researchers can monitor changes longitudinally in the same animal. This approach also supports the reduction and refinement principles of the 3Rs by increasing the information obtained from each animal while reducing the number needed to achieve statistical relevance.
A wide range of imaging technologies contribute to oncology research, providing complementary insights into tumor biology, progression, and treatment response:
Together, these preclinical imaging modalities provide a comprehensive and quantitative understanding of cancer development and treatment response.
Bruker provides a comprehensive portfolio of preclinical imaging solutions for oncology, spanning optical imaging, BLI, FLI, PET, SPECT, MRI, and micro-CT technologies.
These advanced platforms help researchers investigate the mechanisms of tumor progression, evaluate therapeutic efficacy, and accelerate translational cancer research.
Multimodal imaging configurations, including:
Coregistration with optical imaging workflows combine molecular, functional, and anatomical information within a single research framework.
By delivering quantitative 3D visualization of radiotracer uptake, tissue morphology, cellular activity, and molecular pathways, Bruker's preclinical imaging solutions empower researchers to advance discoveries that support the development of safer and more effective cancer treatments.